Most Read Articles
Jairia Dela Cruz, 18 Dec 2018
The use of ixekizumab to selectively target interleukin-17A (IL-17A) in disease-modifying antirheumatic drug-naïve patients with ankylosing spondylitis yields improvements in disease activity, health-related quality of life, day-to-day physical activity, and bone marrow oedema of the spine and sacroiliac joint, according to the results of the phase III COAST-V study.
10 Jan 2019
Only a few sonographic enthesitis scoring instruments developed for spondyloarthritis (SpA) have been validated in psoriatic arthritis (PsA), and none of them passed the Outcome Measures in Rheumatology (OMERACT) filter in patients with PsA, according to a systematic review.

Baricitinib appears to be safe, effective in phase IIb study

03 Feb 2018
Many drugs result in successful laboratory tests but fewer than 12% entering clinical trials end up in pharmacies.

Baricitinib has shown consistent safety and tolerability up to 128 weeks, with no unexpected late signals, according to the results of a phase IIb study in rheumatoid arthritis (RA). In addition, clinical improvements during the 24-week blinded period persist during the open-label extension (OLE).

Treatment-emergent adverse events (AEs) occurred in 63 percent of patients in the 4-mg group and 67 percent in the 8-mg group. Furthermore, serious AE presented in 16 percent and 13 percent, infections in 35 percent and 40 percent, and serious infections in 5 percent and 3 percent of patients, respectively.

All baricitinib groups in the second OLE had similar or lower exposure-adjusted incidence rates for AE compared with the first OLE. There were no opportunistic infections, tuberculosis cases or lymphomas seen through week 128, but there was one death during the first OLE.

In addition, the proportions of patients in both OLE who achieved disease improvement at week 24 were either similar or greater at weeks 76 and 128.

To evaluate the safety and efficacy of baricitinib in RA patients up to 128 weeks, researchers enrolled eligible patients in an initial 52-week OLE following a 24-week blinded period. Patients administered 8-mg baricitinib once daily (QD; n=93) continued with that dose and all others received 4 mg QD (n=108).

Depending on researcher discretion, doses could be increased to 8 mg QD at week 28 or 32 when ≥6 tender and ≥6 swollen joints were present. Those who completed the first OLE were allowed to enter a second 52-week OLE and receive 4 mg QD irrespective of previous dose.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 18 Dec 2018
The use of ixekizumab to selectively target interleukin-17A (IL-17A) in disease-modifying antirheumatic drug-naïve patients with ankylosing spondylitis yields improvements in disease activity, health-related quality of life, day-to-day physical activity, and bone marrow oedema of the spine and sacroiliac joint, according to the results of the phase III COAST-V study.
10 Jan 2019
Only a few sonographic enthesitis scoring instruments developed for spondyloarthritis (SpA) have been validated in psoriatic arthritis (PsA), and none of them passed the Outcome Measures in Rheumatology (OMERACT) filter in patients with PsA, according to a systematic review.